loading...| Preferred Name |
Pentostatin |
|
| Synonyms |
|
|
| Definitions |
A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C732 |
|
| Accepted_Therapeutic_Use_For |
Chronic lymphocytic leukemia; Cutaneous t-cell lymphoma; Hairy cell leukemia |
|
| ALT_DEFINITION |
The active ingredient in a drug that is used to treat hairy cell leukemia and is being studied in the treatment of other types of cancer. Pentostatin blocks a protein needed for cell growth and may kill cancer cells. It is made by a bacterium. It is a type of adenosine deaminase inhibitor. |
|
| CAS_Registry |
53910-25-1 63677-95-2 |
|
| Chemical_Formula |
C11H16N4O4 |
|
| code |
C732 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04) |
|
| Display_Name |
Pentostatin |
|
| FDA_UNII_Code |
395575MZO7 |
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Pentostatin |
|
| Legacy Concept Name |
Pentostatin |
|
| Maps_To |
Pentostatin |
|
| NCI_Drug_Dictionary_ID |
39210 |
|
| NSC Number |
218321 247520 |
|
| PDQ_Closed_Trial_Search_ID |
39210 |
|
| PDQ_Open_Trial_Search_ID |
39210 |
|
| Preferred_Name |
Pentostatin |
|
| prefixIRI |
NCIT:C732 |
|
| prefLabel |
Pentostatin |
|
| Semantic_Type |
Pharmacologic Substance Nucleic Acid, Nucleoside, or Nucleotide Antibiotic |
|
| UMLS_CUI |
C0030896 |
|
| subClassOf |